Author(s):
Pramod Kumar Adusumilli, Bala Sowmya Samanthula, Dharini Boopathi, Deepalakshmi Mani
Email(s):
deepapharmacy@jssuni.edu.in
DOI:
10.52711/0974-360X.2023.00732
Address:
Pramod Kumar Adusumilli, Bala Sowmya Samanthula, Dharini Boopathi, Deepalakshmi Mani
1Department of Pharmacy Practice, Ramaiahuniversity of Applied Sciences, Bangalore 560054, India.
2Department of Pharmacy Practice, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences,
Guntur, Andhra Pradesh, India.
3ADR Monitoring Centre, Karpagam Faculty of Medical Sciences and Research, Coimbatore.
4Pharmacovigilance Programme of India (NCC-PvPI), Indian Pharmacopoeia Commission,
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 10,
Year - 2023
ABSTRACT:
Lennox gastaut syndrome (LGS) is a childhood onset severe epileptic encephalopathy with multiple seizures types usually refractory to pharmacological management. Despite the availability of various anti-epileptic drugs, children with LGS continue to have seizures. LGS refractory to pharmacological treatment leads to poor prognoses like severe intellectual disability and persisting seizures. Dietary treatment along with anti – epileptics can result in less patient exposure to drugs. In this report, we present a case of 11 years old child of LGS with worsening of intellectual disability. Adapting non pharmacological treatment can reduce the patient exposure to drugs and seizure control. Surgical options are recommended when patient doesn’t respond to anti – epileptic drugs. Corpus callosotomy and vagus nerve stimulation are most recent advances in surgical treatment of LGS. Although more data are needed to confirm efficacy of non pharmacological options, in many cases they resulted in complete reduction of seizure.
Cite this article:
Pramod Kumar Adusumilli, Bala Sowmya Samanthula, Dharini Boopathi, Deepalakshmi Mani. Case Report of Lennoxgastaut Syndrome and An Overview of its Non-Pharmacological Treatments. Research Journal of Pharmacy and Technology 2023; 16(10):493-7. doi: 10.52711/0974-360X.2023.00732
Cite(Electronic):
Pramod Kumar Adusumilli, Bala Sowmya Samanthula, Dharini Boopathi, Deepalakshmi Mani. Case Report of Lennoxgastaut Syndrome and An Overview of its Non-Pharmacological Treatments. Research Journal of Pharmacy and Technology 2023; 16(10):493-7. doi: 10.52711/0974-360X.2023.00732 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-10-2
REFERENCES:
1. Arzimanoglou A et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. The Lancet. Neurology. 2009;8(1):82-93. doi:10.1016/S1474-4422(08)70292-8.
2. Hahn, A. Atypical benign partial epilepsy/pseudo-Lennox syndrome. Epileptic disorders : International Epilepsy Journal with Videotape. 2000; 2(1): S11-7.
3. Gibson PA. Lennox-Gastaut syndrome: impact on the caregivers and families of patients. Journal of Multidisciplinary Healthcare. 2014; 7: 441-8. doi:10.2147/JMDH.S69300.
4. Leary PM, Morris S. Recurrent seizures in childhood. Western Cape profile. South African Medical Journal . 1988;74(11):579-1.
5. Chevrie, J J, and J Aicardi. Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 cases. Epilepsia. 1972; 13(2): 259-1. doi:10.1111/j.1528-1157.1972.tb05260.x.
6. Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatric Neurology. 2003;28(3):194-198. doi:10.1016/s0887-8994(02)00513-1.
7. Orange JS et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. The Journal of Allergy and Clinical Immunology. 2006;117(4 Suppl):S525-3. doi:10.1016/j.jaci.2006.01.015.
8. Hemingway C et al. The ketogenic diet: a 3- to 6-year follow-up of 150 children enrolled prospectively. Pediatrics. 2001;108(4):898-5. doi:10.1542/peds.108.4.898.
9. Lemmon ME et al. Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature [published correction appears in Developmental medicine and child neurology. Developmental Medicine and Child Neurology. 2012;54(5):464-8. doi:10.1111/j.1469-8749.2012.04233.x.
10. Cukiert A et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia. 2006;47(2):371-4. doi:10.1111/j.1528-1167.2006.00430.x.
11. Quarato PP et al. Atypical Lennox-Gastaut syndrome successfully treated with removal of a parietal dysembryoplastic tumour. Seizure. 2002;11(5):325-9. doi:10.1053/seiz.2001.0609.
12. Eder HG et al. Gamma knife radiosurgery for callosotomy in children with drug-resistant epilepsy. Child's nervous system :ChNS : official journal of the International Society for Pediatric Neurosurgery. 2006;22(8):1012-7. doi:10.1007/s00381-006-0138-z.
13. Spencer SS et al. Multiple subpial transection for intractable partial epilepsy: an international meta-analysis. Epilepsia. 2002;43(2):141-5. doi:10.1046/j.1528-1157.2002.28101.x.
14. Velasco AL et al. Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. Epilepsia. 2006; 47(7):1203-2. doi:10.1111/j.1528-1167.2006.00593.x.
15. Stepień K et al. Profile of anticonvulsant activity and neuroprotective effects of novel and potential antiepileptic drugs--an update. Pharmacological Reports. 2005;57(6):719-3.
16. Noe' F. Gene therapy in epilepsy: the focus on NPY. Peptides. 2007;28(2):377-3. doi:10.1016/j.peptides.2006.07.025.